Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Niraparib - Janssen/Merck/TESARO

Drug Profile

Niraparib - Janssen/Merck/TESARO

Alternative Names: JNJ-64091742; MK-4827; niraparib hydrochloride; Zejula; ZL 2306

Latest Information Update: 18 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Developer Dana-Farber Cancer Institute; European Network of Gynaecological Oncological Trial Groups; European Organisation for Research and Treatment of Cancer; Georgetown University; Janssen; Katholieke Universiteit Leuven; Merck & Co; Myriad Genetics; NeoGenomics; Resolution Bioscience; Sarcoma Alliance for Research through Collaboration; Takeda; TESARO; Thomas Jefferson University; University Health Network; University of Florida; University of Kansas Medical Center; University of Pennsylvania; University of Utah; ZAI Lab
  • Class Antineoplastics; Benzamides; Indazoles; Piperidines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase 1 inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase III Breast cancer; Prostate cancer; Small cell lung cancer
  • Phase II Cholangiocarcinoma; Endometrial cancer; Mesothelioma; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Uveal melanoma
  • Phase I Ewing's sarcoma; Solid tumours
  • No development reported Haematological malignancies

Most Recent Events

  • 14 Feb 2019 Phase-III clinical trials in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (PO)
  • 14 Feb 2019 Efficacy and adverse events data from the phase III GALAHAD trial in Prostate cancer released by Janssen
  • 22 Jan 2019 Phase-II clinical trials in Pancreatic cancer (Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03553004)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top